Coexistence of Fabry disease with IgM nephropathy

Abstract Rationale: Coexistence of Fabry disease and IgM nephropathy is rare. The varying severity and unapparent clinical manifestation of Fabry disease makes it difficult to recognize when coexisting with another more prevalent cause of nephropathy requiring electron microscopy and genetic testing to confirm their coexistence. Patient concerns: A 54-year-old female presented with proteinuria without any clinical signs or family history of Fabry disease. Diagnoses: Immunostaining of the renal biopsy identified mesangial IgM deposition diagnosing it as IgM nephropathy. The light microscopy indicated prominent vacuolization of podocytes. Further examination of toluidine blue stained semi-thin sections and electron microscopy revealed blue bodies and myelin bodies in the cytoplasm of podocytes, respectively. Mutation analysis detected missense mutation establishing the diagnosis of coexisting Fabry disease. Interventions: The patient was treated with angiotensin-converting enzyme inhibitors. Enzyme replacement therapy was not administered due to financial constraints. Outcomes: After 2 months of treatment the patient demonstrated urine protein to creatinine ratio of 0.21 g/g. Lessons: Identifying coexistence of Fabry disease with other nephropathy requires meticulous pathologic investigations including electron microscopy especially when Fabry disease presents with atypical phenotype.

[1]  T. Connor,et al.  The natural history of immunoglobulin M nephropathy in adults , 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[2]  M. Mubarak,et al.  Immunoglobulin M nephropathy in adults: a clinicopathological study. , 2013, Iranian journal of kidney diseases.

[3]  P. Elliott,et al.  Anderson-Fabry disease and the heart. , 2010, Progress in cardiovascular diseases.

[4]  Manesh R. Patel,et al.  Life expectancy and cause of death in males and females with Fabry disease: Findings from the Fabry Registry , 2009, Genetics in Medicine.

[5]  P. Rozenfeld,et al.  High incidence of autoantibodies in Fabry disease patients , 2007, Journal of Inherited Metabolic Disease.

[6]  R. Schiffmann,et al.  The Relationship of Vascular Glycolipid Storage to Clinical Manifestations of Fabry Disease: A Cross-Sectional Study of a Large Cohort of Clinically Affected Heterozygous Women , 2005, Medicine.

[7]  M. Audran,et al.  Fabry disease: a review. , 2004, Joint, bone, spine : revue du rhumatisme.

[8]  S. Packman,et al.  Fabry Disease, an Under-Recognized Multisystemic Disorder: Expert Recommendations for Diagnosis, Management, and Enzyme Replacement Therapy , 2003, Annals of Internal Medicine.

[9]  J. Tager,et al.  Characterization of antibodies against ceramidetrihexoside and globoside. , 1978, Immunochemistry.